William Go - 02 Feb 2026 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Chief Medical Officer
Signature: /s/ James Pennington, Attorney-in-Fact
Issuer symbol: JANX
Transactions as of: 02 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2026, 20:01:40 UTC
Previous filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Go William	Chief Medical Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO	/s/ James Pennington, Attorney-in-Fact	04 Feb 2026	0002108554

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JANX	Common Stock	Award	$0	+44,000		$0.000000	44,000	02 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock option (right to buy)	Award	$0	+154,000		$0.000000	154,000	02 Feb 2026	Common Stock	154,000	$13.99	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on February 1, 2027.
F2	25% of the shares subject to the option vest on February 26, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.